On Thursday, HealthEquity reached an important technical milestone, with its Relative Strength (RS) Rating jumping into the 80-plus percentile with an upgrade to 83, up from 80 the day before.
Looking For The Best Stocks To Buy And Watch? Start Here
This exclusive rating from Investor's Business Daily identifies share price movement with a 1 (worst) to 99 (best) score. The score shows how a stock's price behavior over the last 52 weeks stacks up against all the other stocks in our database.
Over 100 years of market history shows that the best stocks typically have an RS Rating north of 80 as they begin their biggest price moves.
HealthEquity is trying to complete a cup without handle with a 115.59 buy point. See if it can clear the breakout price in heavy trade.
The company posted 10% earnings growth last quarter, while sales growth came in at 19%. The company is expected to report its latest numbers on or around Jun. 3.
HealthEquity holds the No. 2 rank among its peers in the Commercial Services-Outsourcing industry group. Red Violet is the No. 1-ranked stock within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
